Novel and highly potent histamine H3 receptor ligands. Part 1: withdrawing of hERG activity
Nicolas Levoin, Olivier Labeeuw, Thierry Calmels et al. · Bioorganic & Medicinal Chemistry Letters · 2011
Cited by 21 works. doi:10.1016/j.bmcl.2011.07.006
Authors
- Nicolas Levoin
- Olivier Labeeuw
- Thierry Calmels
- Olivia Poupardin
- Isabelle Berrebi‐Bertrand
- Jeanne‐Marie Lecomte
- Jean-Charles Schwartz
- Marc Capet
References
- The histamine H3 receptor: from gene cloning to H3 receptor drugs
- Synthesis of Potent Non-imidazole Histamine H3-Receptor Antagonists
- Histamine H3 Receptor Antagonists: Preclinical Promise for Treating Obesity and Cognitive Disorders
- Histamine H3 Receptor Antagonists Go to Clinics
- Discovery of Histamine H3 Antagonists for the Treatment of Cognitive Disorders and Alzheimer’s Disease
- Model Selection Based on Structural Similarity−Method Description and Application to Water Solubility Prediction
- A binary QSAR model for classification of hERG potassium channel blockers
- In Silico Binary Classification QSAR Models Based on 4D-Fingerprints and MOE Descriptors for Prediction of hERG Blockage
- H3 Receptors and Pain Modulation: Peripheral, Spinal, and Brain Interactions
- Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics